A Phase 3 interventional study of Abatacept and Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-21.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 35th largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 23rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 35th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 3, and was the 27th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease Activity Score 28 [DAS 28]-erythrocyte sedimentation rate [ESR] \< 2.6) at Day 701 of study IM101023.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Abatacept
Drug: Abatacept
Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)
An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score \>=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).
Time frame: Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Number of Participants Experiencing Disease Relapse
Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score \>= 3.2 at 2 consecutive visits.
Time frame: After 12 Months of treatment
Mean Time-Matched Baseline DAS28 CRP Scores
Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
Time frame: Baseline
Adjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment
Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
Time frame: Baseline, Days 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365
Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)
DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
Time frame: After 12 months of treatment
Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment
Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.
Time frame: After 12 months of treatment
Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids
A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).
Time frame: After 12 months of treatment
Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment
All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.
Time frame: After 12 months of treatment
Percentage of Participants Who Modified Therapy During Double-Blind Treatment
Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.
Time frame: After 12 months of treatment
Percentage of Participants Who Lost Remission Status
Loss of remission is defined as DAS 28 CRP \>=2.6.
Time frame: After 12 months of treatment
Steady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment
Time frame: Day 701 of the main study; sub-study Days 1, 85, 169, 253
Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Percentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment
All neoplasms were assessed by medical review as to whether or not the event was malignant.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Percentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Percentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Percentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity
A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Percentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment
Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(\*)Lymphocytes(c/uL):Low\<.750x10\^3,High\>7.50x10\^3.(\*)Eosinophils:\>.750x10\^3 c/uL.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Clinically Significant Changes in Vital Signs and Physical Findings
Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.
Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Participants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment
A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'
Time frame: After 12 months of treatment
IM101023 (NCT00122382) was a 2-year study completing on Day 729, in which subjects were randomized to receive abatacept or placebo in combination with methotrexate (MTX) for the 1st year of the study and were then switched to open-label abatacept+MTX in the 2nd year. All subjects had received abatacept for a least 1 year prior start of sub-study.
| Milestone | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Started | 58 | 50 |
| Number rescued to open-label treatment | 4 | 4 |
| Number completing double-blind treatment | 51 | 41 |
| Completed | 55 | 44 |
| Not completed | 3 | 6 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Withdrawal of consent | 1 | 1 |
| Withdrew: Desire to become pregnant | 1 | 0 |
| Withdrew: Randomized by mistake | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score \>= 3.2 at 2 consecutive visits.
| Participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Number of Participants Experiencing Disease Relapse | 18 | 17 |
Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
| units on a scale | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Day 29 Cohort (n=45, 40) | 2.09 ± 0.61 | 2.05 ± 0.60 |
| Day 57 Cohort (n=47, 37) | 2.06 ± 0.59 | 2.06 ± 0.62 |
| Day 85 Cohort (n=46, 42) | 2.10 ± 0.60 | 2.09 ± 0.60 |
| Day 113 Cohort (n=49, 39) | 2.06 ± 0.61 | 2.09 ± 0.62 |
| Day 141 Cohort (n=47, 40) | 2.09 ± 0.59 | 2.10 ± 0.62 |
| Day 169 Cohort (n=46, 36) | 2.10 ± 0.59 | 2.04 ± 0.61 |
| Day 197 Cohort (n=44, 38) | 2.08 ± 0.60 | 2.06 ± 0.61 |
| Day 225 Cohort (n=44, 38) | 2.09 ± 0.60 | 2.08 ± 0.63 |
| Day 253 Cohort (n=46, 37) | 2.07 ± 0.60 | 2.04 ± 0.61 |
| Day 281 Cohort (n=45, 38) | 2.07 ± 0.61 | 2.06 ± 0.61 |
| Day 309 Cohort (n=45, 37) | 2.10 ± 0.58 | 2.08 ± 0.61 |
| Day 337 Cohort (n=44, 36) | 2.09 ± 0.60 | 2.08 ± 0.62 |
| Day 365 Cohort (n=41, 35) | 2.02 ± 0.60 | 2.08 ± 0.60 |
Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
| units on a scale | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Day 29 (n=45, 40) | 0.24 ± 0.10 | 0.06 ± 0.10 |
| Day 57 (n=47, 37) | 0.05 ± 0.09 | 0.14 ± 0.10 |
| Day 85 (n=46, 42) | 0.13 ± 0.10 | 0.21 ± 0.10 |
| Day 113 (n=49, 39) | 0.02 ± 0.09 | 0.25 ± 0.10 |
| Day 141 (n=47, 40) | 0.32 ± 0.10 | 0.29 ± 0.11 |
| Day 169 (n=46, 36) | 0.13 ± 0.09 | 0.26 ± 0.11 |
| Day 197 (n=44, 38) | 0.09 ± 0.09 | 0.22 ± 0.09 |
| Day 225 (n=44, 38) | 0.25 ± 0.10 | 0.29 ± 0.10 |
| Day 253 (n=46, 37) | 0.23 ± 0.09 | 0.14 ± 0.10 |
| Day 281 (n=45, 38) | 0.18 ± 0.08 | 0.05 ± 0.09 |
| Day 309 (n=45, 37) | 0.07 ± 0.08 | 0.09 ± 0.09 |
| Day 337 (n=44, 36) | 0.26 ± 0.11 | 0.29 ± 0.13 |
| Day 365 (n=41, 35) | 0.39 ± 0.11 | 0.16 ± 0.12 |
DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status) | 22.4 (11.7 to 33.1) | 22.0 (10.5 to 33.5) |
Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment | 3.4 (-1.2 to 8.1) | 12.0 (3.0 to 21.0) |
A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids | 0 (0 to 0) | 0 (0 to 0) |
An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score \>=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).
| Percentage of Events | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Month 1 (n=55, 49) | 5.17 | 2.00 |
| Month 2 (n=52, 47) | 8.65 | 4.00 |
| Month 3 (n=51, 42) | 10.41 | 12.35 |
| Month 4 (n=50, 38) | 12.17 | 22.78 |
| Month 5 (n=47, 35) | 13.96 | 26.96 |
| Month 6 (n=42, 33) | 23.11 | 31.13 |
| Month 7 (n=41, 32) | 24.94 | 33.22 |
| Month 8 (n=40, 31) | 26.77 | 33.22 |
| Month 9 (n=38, 31) | 30.43 | 33.22 |
| Month 10 (n=37, 31) | 32.27 | 33.22 |
| Month 11 (n=37, 30) | 32.27 | 35.37 |
| Month 12 (n=36, 28) | 32.27 | 35.37 |
All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment | 6.9 (0.4 to 13.4) | 8.0 (0.5 to 15.5) |
Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants Who Modified Therapy During Double-Blind Treatment | 10.3 (2.5 to 18.2) | 18.0 (7.4 to 28.6) |
Loss of remission is defined as DAS 28 CRP \>=2.6.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants Who Lost Remission Status | 53.4 (40.6 to 66.3) | 64.0 (50.7 to 77.3) |
| ng/mL | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Main Study Day 701 (n=41, 36) | 22992.0 ± 9722.1 | 21713.5 ± 9520.5 |
| Sub-Study Day 1 (n=46, 41) | 22213.0 ± 9275.8 | 23620.7 ± 9648.0 |
| Sub-Study Day 85 (n=47, 43) | 24919.5 ± 14516.2 | 11922.1 ± 5681.8 |
| Sub-Study Day 169 (n=48, 43) | 25725.7 ± 18500.5 | 9959.2 ± 5045.0 |
| Sub-Study Day 253 (n=47, 42) | 28524.7 ± 19989.9 | 13516.2 ± 6564.6 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Deaths | 0 | 2.0 |
| SAEs | 5.2 | 6.0 |
| Related SAEs | 1.7 | 0 |
| Discontinued due to SAEs | 0 | 2.0 |
| AEs | 65.5 | 50.0 |
| Related AEs | 20.7 | 10.0 |
| Discontinued due to AEs | 0 | 2.0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Total Participants with Infection and Infestation | 37.9 | 26.0 |
| Upper Respiratory Tract Infection | 5.2 | 12.0 |
| Nasopharyngitis | 5.2 | 6.0 |
| Influenza | 5.2 | 4.0 |
| Bronchitis | 5.2 | 2.0 |
| Urinary Tract Infection | 3.4 | 4.0 |
| Onychomycosis | 3.4 | 2.0 |
| Pharyngitis | 3.4 | 2.0 |
| Rhinitis | 3.4 | 2.0 |
| Ear Infection | 3.4 | 0 |
| Vaginal Infection | 3.4 | 0 |
| Appendicitis | 1.7 | 0 |
| Furuncle | 1.7 | 0 |
| Pneumonia | 1.7 | 0 |
| Sinusitis Bacterial | 1.7 | 0 |
| Endocarditis | 0 | 2.0 |
| Fungal Skin Infection | 0 | 2.0 |
| Herpes Simplex | 0 | 2.0 |
| Labyrinthitis | 0 | 2.0 |
| Oral Herpes | 0 | 2.0 |
| Respiratory Tract Infection | 0 | 2.0 |
| Sinusitis | 0 | 2.0 |
All neoplasms were assessed by medical review as to whether or not the event was malignant.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment | 0 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Total Participants with AIAEs (mild) | 0 | 2.0 |
| Total Participants with AIAEs (moderate) | 0 | 0 |
| Total Participants with AIAEs (severe) | 0 | 0 |
| Total Participants with AIAEs (very severe) | 0 | 0 |
| Vascular Disorders - Hypertension (mild) | 0 | 2.0 |
| Vascular Disorders - Hypertension (moderate) | 0 | 0 |
| Vascular Disorders - Hypertension (severe) | 0 | 0 |
| Vascular Disorders - Hypertension (very severe) | 0 | 0 |
| Vascular Disorders - Hypertension (unknown) | 0 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Total Participants with PIAEs (mild) | 6.9 | 4.0 |
| Total Participants with PIAEs (moderate) | 1.7 | 0 |
| Total Participants with PIAEs (severe) | 0 | 0 |
| Total Participants with PIAEs (very severe) | 0 | 0 |
| Gastrointestinal Disorders, Nausea (mild) | 1.7 | 0 |
| Gastrointestinal Disorders, Nausea (moderate) | 0 | 0 |
| Gastrointestinal Disorders, Nausea (severe) | 0 | 0 |
| Gastrointestinal Disorders, Nausea (very severe) | 0 | 0 |
| Gastrointestinal Disorders, Vomiting (mild) | 1.7 | 0 |
| Gastrointestinal Disorders, Vomiting (moderate) | 0 | 0 |
| Gastrointestinal Disorders, Vomiting (severe) | 0 | 0 |
| Gastrointestinal Disorders, Vomiting (very severe) | 0 | 0 |
| Nervous System Disorders, Dizziness (mild) | 1.7 | 0 |
| Nervous System Disorders, Dizziness (moderate) | 0 | 0 |
| Nervous System Disorders, Dizziness (severe) | 0 | 0 |
| Nervous System Disorders, Dizziness (very severe) | 0 | 0 |
| Nervous System Disorders, Headache (mild) | 0 | 0 |
| Nervous System Disorders, Headache (moderate) | 1.7 | 0 |
| Nervous System Disorders, Headache (severe) | 0 | 0 |
| Nervous System Disorders, Headache (very severe) | 0 | 0 |
| GDASC, Malaise (mild) | 1.7 | 0 |
| GDASC, Malaise (moderate) | 0 | 0 |
| GDASC, Malaise (severe) | 0 | 0 |
| GDASC, Malaise (very severe) | 0 | 0 |
| GDASC, Chest Pain (mild) | 0 | 2.0 |
| GDASC, Chest Pain (moderate) | 0 | 0 |
| GDASC, Chest Pain (severe) | 0 | 0 |
| GDASC, Chest Pain (very severe) | 0 | 0 |
| RTMD, Asthma (mild) | 1.7 | 0 |
| RTMD, Asthma (moderate) | 0 | 0 |
| RTMD, Asthma (severe) | 0 | 0 |
| RTMD, Asthma (very severe) | 0 | 0 |
| RTMD, Cough (mild) | 1.7 | 0 |
| RTMD, Cough (moderate) | 0 | 0 |
| RTMD, Cough (severe) | 0 | 0 |
| RTMD, Cough (very severe) | 0 | 0 |
| Vascular Disorders, Hypertension (mild) | 0 | 2.0 |
| Vascular Disorders, Hypertension (moderate) | 0 | 0 |
| Vascular Disorders, Hypertension (severe) | 0 | 0 |
| Vascular Disorders, Hypertension (very severe) | 0 | 0 |
A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Total Participants with ADs (mild) | 0 | 4.0 |
| Total Participants with ADs (moderate) | 0 | 0 |
| Total Participants with ADs (severe) | 0 | 0 |
| Total Participants with ADs (very severe) | 0 | 0 |
| Eye Disorders - Episcleritis (mild) | 0 | 2.0 |
| Eye Disorders - Episcleritis (moderate) | 0 | 0 |
| Eye Disorders - Episcleritis (severe) | 0 | 0 |
| Eye Disorders - Episcleritis (very severe) | 0 | 0 |
| MCTDs - Sjogren's Syndrome (mild) | 0 | 2.0 |
| MCTDs - Sjogren's Syndrome (moderate) | 0 | 0 |
| MCTDs - Sjogren's Syndrome (severe) | 0 | 0 |
| MCTDs - Sjogren's Syndrome (very severe) | 0 | 0 |
Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(\*)Lymphocytes(c/uL):Low\<.750x10\^3,High\>7.50x10\^3.(\*)Eosinophils:\>.750x10\^3 c/uL.
| percentage of participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| Hemoglobin, Low: >3 g/dL ↓ from pre rx (n=51, 48) | 0 | 0 |
| Hematocrit, Low: <0.75 x pre rx (n=51, 48) | 0 | 0 |
| Erythrocytes, Low: <0.75 x pre rx (n=51, 48) | 0 | 0 |
| ALP, High: >2 x upper limit normal (ULN)(n=52, 47) | 0 | 0 |
| Total Calcium, Low: <0.8 x Lower LN(LLN)(n=52, 47) | 0 | 0 |
| Platelet Count, Low: <0.67 x LLN (n=51, 48) | 0 | 0 |
| Platelet Count, High: >1.5 x ULN (n=51, 48) | 0 | 0 |
| Leukocytes, Low: <0.75 x LLN (n=51, 48) | 0 | 0 |
| N+B (absolute), Low: < 1.00 x 10^3 c/uL (n=55, 49) | 0 | 0 |
| Lymphocytes (absolute), Low (*) (n=55, 49) | 1.8 | 2.0 |
| Lymphocytes (absolute), High (*) (n=55, 49) | 0 | 0 |
| Monocytes (absolute), High: >2000/mm^3 (n=55, 49) | 0 | 0 |
| Basophils (absolute), High: > 400/mm^3 (n=55, 49) | 0 | 0 |
| Eosinophils (absolute), High (*) (n=55, 49) | 5.5 | 2.0 |
| AST, High: >3 x ULN (n=52, 47) | 0 | 0 |
| ALT, High: >3 x ULN (n=52, 47) | 0 | 0 |
| GGT, High: >2 x ULN (n=52, 47) | 0 | 0 |
| Bilirubin Total, High: >1.5 x ULN (n=52, 46) | 0 | 0 |
| Blood Urea Nitrogen, High: >2 x pre rx (n=52, 47) | 0 | 0 |
| Serum Sodium, Low: <0.95 x LLN (n=52, 47) | 0 | 0 |
| Serum Sodium, High: >1.05 x ULN, (n=52, 47) | 0 | 0 |
| Serum Potassium, Low: <0.9 x LLN (n=52, 47) | 0 | 0 |
| Serum Potassium, High: >1.1 x ULN (n=52, 47) | 0 | 2.1 |
| Serum Chloride, Low: <0.9 x LLN (n=52, 47) | 0 | 0 |
| Serum Chloride, High: >1.1 x ULN, (n=52, 47) | 0 | 0 |
| Total Calcium, High: >1.2 x ULN (n=52, 47) | 0 | 0 |
| Inorganic Phosphorus, Low: <0.75 x LLN (n=52, 47) | 0 | 0 |
| Inorganic Phosphorus, High: >1.25 x ULN (n=52, 47) | 0 | 0 |
| Serum Glucose, Low: <65 mg/dL (n=55, 48) | 5.5 | 6.3 |
| Serum Glucose, High: >220 mg/dL (n=55, 48) | 3.6 | 4.2 |
| Total Protein, Low: <0.9 x LLN (n=52, 47) | 0 | 0 |
| Total Protein, High: >1.1 x ULN (n=52, 47) | 0 | 0 |
| Albumin, Low: <0.9 x LLN (n=52, 47) | 0 | 0 |
| Uric Acid, High: >1.5 x ULN (n=52, 47) | 0 | 0 |
| Urine Protein, High: >=2-4 (n=55, 47) | 1.8 | 6.4 |
| Urine Glucose, High: >=2-4 (n=55, 47) | 5.5 | 0 |
| Urine Blood, High: >=2-4 (n=55, 47) | 12.7 | 10.6 |
| Urine Leukocyte Esterase, High: >=2-4 (n=20, 16) | 15.0 | 25.0 |
| Urine White Blood Cells, High: >=2-4 (n=22, 14) | 45.5 | 14.3 |
| Urine Red Blood Cells, High: >=2-4 (n=22, 14) | 22.7 | 28.6 |
Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.
No measurements were reported for this outcome.
A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'
| participants | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) |
|---|---|---|
| CTLA4 and Possibly IG | 4 | 1 |
| IG and/or Junction Region | 0 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept 5mg/kg (ST) | — | 3/50 (6%) | 17/50 (34%) |
| Abatacept 10mg/kg (ST) | — | 3/58 (5.2%) | 18/58 (31%) |
| Abatacept 10mg/kg (Open-Label) | — | 2/8 (25%) | 7/8 (87.5%) |
| Event | Abatacept 5mg/kg (ST) | Abatacept 10mg/kg (ST) | Abatacept 10mg/kg (Open-Label) |
|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/50 | 0/58 | 1/8 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/50 | 0/58 | 1/8 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 2/50 | 0/58 | 0/8 |
| LeukopeniaBlood and lymphatic system disorders | 1/50 | 0/58 | 0/8 |
| NeutropeniaBlood and lymphatic system disorders | 1/50 | 0/58 | 0/8 |
| Cardiopulmonary FailureCardiac disorders | 1/50 | 0/58 | 0/8 |
| EndocarditisInfections and infestations | 1/50 | 0/58 | 0/8 |
| Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders | 1/50 | 0/58 | 0/8 |
| Renal Failure AcuteRenal and urinary disorders | 1/50 | 0/58 | 0/8 |
| AppendicitisInfections and infestations | 0/50 | 1/58 | 0/8 |
| Event | Abatacept 5mg/kg (ST) | Abatacept 10mg/kg (ST) | Abatacept 10mg/kg (Open-Label) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/50 | 0/58 | 2/8 |
| ConjunctivitisEye disorders | 2/50 | 0/58 | 1/8 |
| XerophtalmiaEye disorders | 0/50 | 0/58 | 1/8 |
| Abdominal DistensionGastrointestinal disorders | 1/50 | 0/58 | 1/8 |
| Abdominal Pain UpperGastrointestinal disorders | 0/50 | 0/58 | 1/8 |
| Hiatus HerniaGastrointestinal disorders | 0/50 | 0/58 | 1/8 |
| VomitingGastrointestinal disorders | 0/50 | 1/58 | 1/8 |
| NasopharyngitisInfections and infestations | 3/50 | 3/58 | 1/8 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/50 | 3/58 | 1/8 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/50 | 1/58 | 1/8 |
| Age Continuous(years) | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) | Total |
|---|---|---|---|
| Mean | 50.1 ± 11.5 | 51.1 ± 13.4 | 50.6 ± 12.3 |
| Sex: Female, Male(Participants) | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) | Total |
|---|---|---|---|
| Female | 44 | 41 | 85 |
| Male | 14 | 9 | 23 |
| Race/Ethnicity, Customized(participants) | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) | Total |
|---|---|---|---|
| Unknown | 2 | 0 | 2 |
| White | 49 | 46 | 95 |
| Black | 2 | 0 | 2 |
| Asian | 2 | 2 | 4 |
| Other | 3 | 2 | 5 |
| Weight(kg) | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) | Total |
|---|---|---|---|
| Mean | 72.9 ± 14.7 | 73.8 ± 16.0 | 73.4 ± 15.3 |
| Disease Activity Scores Using C-reactive Protein (DAS 28 [CRP])(units on a scale) | Abatacept (10 mg/kg) | Abatacept (5 mg/kg) | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.6 | 2.1 ± 0.6 | 2.1 ± 0.6 |
No study locations are listed for this record.
The record gives a start of Apr 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept